CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 150 enrolled
Drug / intervention
Olopatadine HCl Nasal Spray, 0.6% +1 moredrug
Likely dose
Olopatadine HCl Nasal Spray, 0.6% 50 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00845195
NCT00845195Phase 4Completed
CompareCT.gov

Comparison of Seasonal Allergic Rhinitis Treatment With 2 Antihistamines Used in Combination With Intranasal Corticosteroid

Alcon Research·interventional·Posted Feb 18, 2009·Updated Apr 27, 2010

In Brief

A Phase 4 clinical trial evaluating Olopatadine HCl Nasal Spray, 0.6% and Azelastine HCl Nasal Spray, 0.1% for Seasonal Allergic Rhinitis. Completed, enrolled 150 participants across 1 site.

Detailed Summary

The purpose of this study is to compare the efficacy of Olopatadine Nasal Spray with Azelastine Nasal Spray when treatments are utilized in conjunction with Fluticasone Nasal Spray for the treatment of seasonal allergic rhinitis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSeasonal Allergic Rhinitis
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 18, 2009
Enrollment StartMar 1, 2009
Primary CompletionMay 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 17.4 years ago

Interventions

Olopatadine HCl Nasal Spray, 0.6%drug

2 sprays/nostril, twice daily (in addition to Fluticasone Propionate Nasal Spray 50 mcg 2 sprays/nostril once daily) for 14 +/- 3 days

Azelastine HCl Nasal Spray, 0.1%drug

2 sprays/nostril, twice daily (in addition to Fluticasone Propionate Nasal Spray 50 mcg 2 sprays/nostril once daily) for 14 +/- 3 days